Fixed-duration cytarabine consolidation improves relapse-free survival over indefinite AZA–VEN in younger AML

Blood Cancer Journal 2026 Open access

Read full text
Authors: Rudra Narayan Swain, Arihant Jain, Sarthak Wadhera, Charanpreet Singh, Aditya Jandial, Alka Khadwal, Man Updesh Sachdeva, Shano Naseem, Pankaj Malhotra, Gaurav Prakash
DOI: 10.1038/s41408-026-01492-0
Cited by: 1
References: 18

Abstract

The treatment of newly diagnosed Acute Myeloid Leukaemia (ND-AML) requires a personalised approach based on age, comorbidities, and functional status of a patient. The azacitidine–venetoclax (Aza-Ven) regimen, though initially approved for elderly or unfit patients, is now increasingly used in younger adults (

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Hematopoietic Stem Cell Transplantation

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
15 April 2026
Language
EN